As of late, stock analysts have maintained a bullish outlook on Charles River Laboratories International, with Baird reasserting its Outperform Rating. JP Morgan Chase & Co., Hillsdale Investment Management Inc. and Vanguard Group Inc., for instance, all augmented their respective stake in CRL's stock. The company's consistent performance has caught investors' attention, especially following its recent earnings beat and the latest fiscal year 2025 results which included improved forecasts for 2026.
On the horizon for Charles River is a calculated move towards financial streamlining. It plans to divest certain European assets and businesses, including the CDMO, Cell Solutions, and European discovery operations, which are being acquired by IQVIA Holdings Inc. This action has received a positive response from the market, prompting its stock price to surge by 4.7%. It has also led to executive appointments and structural changes, with Glenn Coleman named the new CFO.
Despite the sale of several assets, Charles River is expected to continue expanding its global market share and maintain its competitive edge, forecasting a positive \u2018cash machine\u2019 status for prospective buyers.
Charles River Laboratories International CRL News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 28 Feb 2026 07:03:07 GMT - Rating 8 - Innovation 5 - Information 6 - Rumor -7
